Noninvasive and Transient Blood-Brain Barrier Opening in the Hippocampus of Alzheimer's Double Transgenic Mice Using Focused Ultrasound

The spatio-temporal nature of focused ultrasound-induced blood-brain barrier (BBB) opening as a brain drug delivery method was investigated in Alzheimer's disease model mice. The left hippocampus of transgenic (APP/PS1, n = 3) and nontransgenic (n = 3) mice was sonicated (frequency: 1.525 MHz, peak-negative pressure: 600 kPa, pulse length: 20 ms, duty cycle: 20%, duration: 1 min) in vivo, through their intact skin and skull, after intravenous injection of microbubbles (SonoVue®5; 25 μl). Sequential, high-field MR images (9.4 Tesla) were acquired before and after injection of gadolinium (Omniscan™ 0.75 ml, molecular weight: 573.7 Da) on two separate days for each mouse. Gadolinium deposits through the ultrasound-induced BBB opening in the left hippocampus revealed significant contrast-enhancement in the MRI. On the following day, MRI revealed significant BBB closure within the same region. However, the BBB opening extent and BBB closing timeline varied in different regions within the same sonicated location. This indicates that opening and closing were dependent on the brain region targeted. No significant difference in BBB opening or closing behaviors was observed between the APP/PS1 and the nontransgenic mice. In conclusion, a BBB-impermeable molecule was noninvasively, transiently and reproducibly delivered to the hippocampus of Alzheimer's APP/PS1 mice.

[1]  M. Hüll,et al.  Disease-modifying therapies in Alzheimer's disease: how far have we come? , 2006, Drugs.

[2]  B. Winblad,et al.  The integrity of the blood–brain barrier in Alzheimer’s disease , 2007, Acta neurologica Scandinavica.

[3]  F. Sherriff,et al.  Memantine for dementia. , 2005, The Cochrane database of systematic reviews.

[4]  B. Winblad,et al.  The Magnitude of Dementia Occurrence in the World , 2003, Alzheimer disease and associated disorders.

[5]  M. Pernot,et al.  Feasibility of transcranial, localized drug-delivery in the brain of Alzheimer's-model mice using focused ultrasound , 2005, IEEE Ultrasonics Symposium, 2005..

[6]  木下 学.  Noninvasive localized delivery of Herceptin to the mouse brain by MRI-guided focused ultrasound-induced blood-brain barrier disruption , 2007 .

[7]  H. Kundel,et al.  Magnetic resonance imaging observations of blood-brain-barrier permeability in an animal model of brain injury. , 1997, Academic radiology.

[8]  C. Albright,et al.  Gamma-secretase inhibitors for Alzheimer's disease: balancing efficacy and toxicity. , 2006, Drugs in R&D.

[9]  W. Pardridge.  Drug Targeting to the Brain , 2007, Pharmaceutical Research.

[10]  J. Weber,et al.  Blood-Brain Barrier Disruption By Low-Frequency Ultrasound , 2006, Stroke.

[11]  U. Tuor,et al.  Blood‐eye barriers in the rat: Correlation of ultrastructure with function , 1994, The Journal of comparative neurology.

[12]  S. Batra,et al.  Engineering antibodies for clinical applications. , 2007, Trends in biotechnology.

[13]  John G. Sled,et al.  Three-dimensional cerebral vasculature of the CBA mouse brain: A magnetic resonance imaging and micro computed tomography study , 2007, NeuroImage.

[14]  K. Hynynen,et al.  Targeted disruption of the blood–brain barrier with focused ultrasound: association with cavitation activity , 2006, Physics in medicine and biology.

[15]  K. Hynynen,et al.  Multiphoton Imaging of Ultrasound/Optison Mediated Cerebrovascular Effects in vivo , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[16]  J. Hardy,et al.  Increased amyloid-β42(43) in brains of mice expressing mutant presenilin 1 , 1996, Nature.

[17]  Natalia Vykhodtseva,et al.  Targeted delivery of doxorubicin to the rat brain at therapeutic levels using MRI‐guided focused ultrasound , 2007, International journal of cancer.

[18]  S A Small,et al.  Spatio-temporal analysis of molecular delivery through the blood–brain barrier using focused ultrasound , 2007, Physics in medicine and biology.

[19]  J. Vacca,et al.  Progress toward a practical BACE-1 inhibitor. , 2007, Current opinion in drug discovery & development.

[20]  D. Dickson,et al.  Amyloid Phenotype Characterization of Transgenic Mice Overexpressing both Mutant Amyloid Precursor Protein and Mutant Presenilin 1 Transgenes , 1999, Neurobiology of Disease.

[21]  R J Harvey,et al.  Donepezil for dementia due to Alzheimer's disease. , 2006, The Cochrane database of systematic reviews.

[22]  C. Albright,et al.  γ-Secretase Inhibitors for Alzheimer’s Disease , 2006 .

[23]  James J. Choi,et al.  Noninvasive Blood-Brain Barrier Opening in Live Mice , 2006 .

[24]  K. Hynynen,et al.  Noninvasive MR imaging-guided focal opening of the blood-brain barrier in rabbits. , 2001, Radiology.

[25]  T. Brown,et al.  Longitudinal mapping of mouse cerebral blood volume with MRI , 2006, NMR in biomedicine.

[26]  S. Younkin,et al.  Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice , 1996, Science.

[27]  James J. Choi,et al.  Noninvasive, transcranial and localized opening of the blood-brain barrier using focused ultrasound in mice. , 2007, Ultrasound in medicine & biology.